Partikula Overview
- Founded
-
2013

- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Partikula General Information
Description
Developer of novel therapeutics designed to treat oncology and other diseases. The company's therapeutics utilize proprietary chemical engineering technologies to develop compounds that specifically and directly target mitochondria, from the outer mitochondrial membrane to the mitochondrial matrix and areas in between, enabling patients to fight off a large number of major diseases including cancer, neurodegenerative disease, cardiovascular and metabolic disease and a number of rare orphan diseases.
Contact Information
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Primary Office
- 15491 South West 12th Street
- Suite 408
- Sunrise, FL 33326
- United States
+1 (954) 000-0000
Partikula Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Out of Business | 01-Apr-2018 | 00.000 | Completed | Out of Business | ||
4. Debt - General | 30-Jun-2016 | 00.000 | Completed | Startup | ||
3. Debt - General | 20-Nov-2015 | 00.000 | Completed | Startup | ||
2. Early Stage VC (Series A) | 02-Feb-2015 | $5M | $5.15M | Completed | Startup | |
1. Angel (individual) | 25-Mar-2014 | $150K | $150K | Completed | Startup |
Partikula Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel therapeutics designed to treat oncology and other diseases. The company's therapeutics utilize propri
Biotechnology
Sunrise, FL
00.000
00000000 00
00.000
Partikula Competitors (2)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Larimar Therapeutics | Formerly VC-backed | Bala Cynwyd, PA | 00 | 00000 | 000000000 | |
000000 | Formerly VC-backed | Lund, Sweden | 0 | 000.00 | 000000000 | 000.00 |
Partikula Patents
Partikula Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20180028647-A1 | Modifications of therapeutic agents for enhanced delivery to target sites | Granted | 27-Jul-2016 | 000000000 | |
US-10478492-B2 | Modifications of therapeutic agents for enhanced delivery to target sites | Active | 27-Jul-2016 | 000000000 |
Partikula Executive Team (4)
Partikula Board Members (4)
Name | Representing | Role | Since |
---|---|---|---|
David Kolb | Self | Chief Executive Officer, Co-Founder & Board Member | 000 0000 |